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Cytokines are important modulators of inflammation.
The balance between pro- and anti-inflammatory cytokines
determines whether the intensity of inflammatory response
is within physiological limits or in the pathological range. The
cytokine network is highly complex, containing interactive
cascades of gene activation and suppression. Both chronic
kidney disease (CKD) and end-stage renal disease (ESRD) are
characterized by elevated levels of proinflammatory
cytokines and markers of inflammation. Cytokines may
modulate the risk for progression of renal disease and the
susceptibility to cardiovascular disease (CVD). Polymorphisms
of cytokine genes may influence gene transcription and
cytokine secretion and thereby modulate the risk of
progression of renal and CVDs. The observed inconsistencies
in the data regarding associations between single-nucleotide
gene polymorphisms (SNPs) and their presumed phenotypic
expression emphasize the need to recognize several
conceptual and methodological aspects such as haplotypic
rather than single SNP variations and the influence of
pathway genes with synergistic or antagonistic effects that
ultimately determine the phenotype. It is conceivable that
when a patient with a high-risk cytokine genotype develops
CKD, the risk for CVD is increased. Early interventions in CKD
patients with high-risk genotypes may slow the progression
of renal disease and also decrease CV mortality and
morbidity.
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Cytokines are soluble polypeptides acting as important
humoral modulators in immunoregulation, hematopoiesis,
and the inflammatory cascade. Cytokines act in a highly
complex coordinated network with autocrine and paracrine
attributes. Many cytokines appear to be pleiotropic in their
actions, with considerable overlap and redundancy between
the function of individual cytokines. Patients with chronic
kidney disease (CKD) have markedly elevated levels of
cytokines. Although all available evidence indicates upregula-
tion of proinflammatory cytokine activity in CKD, the
etiology of this is largely unknown. The emerging evidence
suggests that cytokines may play a vital regulatory role in the
initiation and progression of CKD and cardiovascular
diseases (CVDs).
THE EPIDEMIC OF CKD
The incidence and prevalence of CKD in the United States is
rapidly increasing; nearly 3% of the US adult population was
noted to have an elevated serum creatinine in the Third
National Health and Nutrition Examination Survey
(NHANES III).1 The burden of morbidity and mortality
from CKD derives not only from the progression to end-stage
renal disease (ESRD) but also the associated risk of CVD that
stems from the cumulative effects of multiple risk factors
from the early stages of CKD. CKD has profound economic
implications for the health-care system, as it is consistently
associated with increased risk of hospitalization, CV events,
and death. Although some traditional (‘Framingham’) risk
factors such as older age, male gender, Caucasian race, family
history, and cigarette smoking, contribute to disease among
patients with CKD, just as they do in the general population,
other risk factors, including hypertension, diabetes/insulin
resistance, and dyslipidemia occur with a higher prevalence
and/or severity in patients with CKD than in the general
population.
THE ROLE OF INFLAMMATION IN CVD AND CKD
Epidemiological studies have demonstrated that inflam-
mation is an important link between CKD and CVD.
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Preliminary evidence suggests a fundamental role for innate
and adaptive immunity in the pathogenesis of CVD as well as
progression of CKD. Patients with CKD have higher
circulating levels of cytokines and dysregulated cytokine
metabolism, leading to elevated levels of acute phase proteins.
The role of chronic inflammation in atherosclerotic coronary
artery disease (CAD), stroke, and peripheral vascular disease
is well established; elevated C-reactive protein (CRP) is a
proven marker for atherosclerosis and CV mortality in the
general population as well as among patients with CKD/
ESRD. Studies in animal models have highlighted the
fundamental role for innate and adaptive immunity in all
stages of atherosclerosis.2,3 Toll-like receptors recognize
pathogen-associated molecular patterns. They are also
activated by endogenous pro-atherosclerotic ligands such as
oxidized low-density lipoprotein and CRP. Activation of Toll-
like receptors also induces cytokine effectors, including
tumor necrosis factor-alpha and -beta (TNF-a and -b),
interleukin-1 beta (IL-1b), IL-1 receptor antagonist (IL-1Ra),
and IL-6. Cytokine receptors (TNF receptors – TNFR1 and
R2, TNFRSF1A and 1B; IL-1 receptors – IL-1R1 and R2; IL6
receptors – IL-6R and IL-6ST), in turn, modulate bioactivity
of their respective cytokines.4 Toll-like receptors and
cytokines activate transcription factors – mitogen-activated
protein kinases, p38, and nuclear factor-kB that in turn
modulate transcription of cytokine effector molecules.
Vascular endothelial, smooth muscle, and mononuclear cells
are the source of a number of these cytokines and growth
factors, including IL-1, TNF-a, transforming growth factor-
beta (TGF-b), platelet-derived growth factor and fibroblast
growth factor.5 These molecules potentially modulate the
phenotypic expression of neighboring cells in a paracrine
manner and themselves in an autocrine manner, including
transformation of smooth muscle cells from contractile to
synthetic phenotype, leading to cell proliferation.6
In CKD, once a critical proportion of nephron mass is
lost, ‘nonspecific’ glomerular and tubulointerstitial scarring
results, which is characteristic of all forms of CKD. The final
common pathway of mechanisms of progression of renal
disease includes intraglomerular hypertension, hyperfiltra-
tion in the remnant glomeruli, systemic hypertension, poor
glycemic control (in diabetics), mesangial, endothelial, and
epithelial injury from protein and macromolecular traffick-
ing, and hyperphosphatemia. Progressive and relentless
glomerular injury is also facilitated by inflammatory and
profibrotic cytokines.7–9 Cytokines modulate the glomerular
response to infectious, dietary, and environmental antigens,
and hence influence the progression of CKD.10 In the kidney,
cytokines induce (a) resident cells to proliferate,11 (b)
aberrant matrix metabolism,12,13 (c) procoagulant activity
of endothelium,14 (d) reactive oxygen/nitrogen species,15 and
expression of (e) adhesion receptors,16 bioactive lipids,17 and
metalloproteinase.18 These molecules may be the effectors
through which the renin–angiotensin system and hemo-
dynamic factors mediate their actions.9 Increasing levels of
angiotensin II in CKD may upregulate the expression of
growth factors and cytokines, such as TGF-b1, TNF-a,
osteopontin, vascular cell adhesion molecule-1, nuclear
factor-kB, platelet-derived growth factor, fibroblast growth
factor, and insulin-like growth factor.19–21 Angiotensin II also
stimulates oxidative stress, which upregulates the expression
of adhesion molecules, chemo-attractant compounds, and
cytokines. Nuclear factor-kB stimulates the angiotensinogen
gene, and is in turn activated by angiotensin II providing an
autocrine reinforcing loop.22
GENETIC RISK IN CKD AND CVD
The progression of renal disease varies not only with the
etiology of underlying renal disease but also among patients
with same type of renal disease.23 Familial clustering of CKD
and ESRD has been appreciated, indicating the presence of a
genetic component. Freedman and co-workers24 observed
heritability of ESRD among large African-American families.
Among index cases with type II diabetes mellitus and ESRD,
37% reported a close relative with ESRD; in contrast, only
7% of age- and gender-matched individuals with type II
diabetes mellitus without nephropathy reported ESRD in
close relatives. Likewise, family history is an important
independent risk factor for CAD and many risk factors
for CVD, such as lipid levels, hypertension, obesity, diabetes,
and the metabolic syndrome, show significant heritability
in family- and population-based epidemiological studies.
Genetic risk may also play a role in the disparities in
CVD-related mortality among ESRD patients from different
countries. A recent ecological study highlighted the strong
correlation to underlying rates of CVD in the respective
general populations; indeed, gene polymorphisms may
explain a large part of the ethnic and mortality differences
among dialysis populations (see Table 1 for a glossary of
common terms).25
Emerging studies of complex human disease provide
compelling evidence for multilocus effects on common
traits.26 The spectrum of CKD and ESRD, and their
complications such as CVD are typical examples of complex
disorders, which in contrast to Mendelian or monogenic
disorders, demonstrate a phenotype controlled by multiple
genes (polygenic, locus heterogeneity) and multiple biologi-
cal pathways. The contribution of each gene is small (low
genotypic relative risk). Phenotypic expression is character-
ized by variable severity and/or definition and context
dependency, and is often modified by gene–environment
interactions and gene–gene interactions (epistasis). The rate
of progression of renal disease and propensity to CVD is seen
to vary widely among patients with CKD, even when
corrected for ethnicity, the etiology of renal disease, and
comorbid conditions. Preliminary evidence suggests that
cytokine genes influence transcription and function as a
result of natural variations in their sequences (i.e. single-
nucleotide polymorphisms (SNPs)). They are attractive as
candidate genes modulating the risk for both CKD and its
complications. Candidate gene association studies are a
powerful approach for the identification of common genetic
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variants involved in common diseases. This is especially true
of studies in the context of CKD and ESRD, where the
existence of multiple physiological trade-offs and reverse
causality give rise to extensive confounding influences. The
concept of Mendelian randomization, the random assort-
ment of alleles from parent to offspring at gamete formation,
could potentially strengthen such designs.
CYTOKINE GENE POLYMORPHISMS AND THE COMPLEXITY OF
CYTOKINE GENE REGULATION
Stimulation of human blood samples with bacterial lipopo-
lysaccharide shows large interindividual variations in the
production of cytokines, a likely function of genetic
variability (Table 2). About 11 million SNPs with minor
allele frequencies of at least 1% are estimated to exist in the
human genome. Fewer SNPs, perhaps 250 000, are thought to
have functional significance because they occur in coding
regions, splice junctions, and promoter regions. Several allelic
polymorphisms of cytokine genes that regulate gene
transcription are of demonstrable clinical significance
(http://www.nanea.dk/cytokinesnps/). Several twin studies
have also confirmed significant heritability in circulating
cytokine and CRP levels.38,39
The existence of complex systems that make up cytokine
networks makes the elucidation of cytokine-gene effects in
complex diseases a significant challenge. The possibility that
single genes, with small effects, could contribute substantially
to disease through interaction with other genes and
environment has been the conceptual breakthrough facilitat-
ing the analysis of genetic data in such settings. This
approach has given rise to the need to examine the role of
individual genes in the context of other pathway genes with
synergistic or antagonistic effects. It has also underlined the
need to know more comprehensively the complete genetic
variation within a candidate gene and the structure of linkage
disequilibrium in the region (see next section on the concept
of haplotype variation). Failure of replication has been a
frequent obstacle vitiating progress in the field; replication
validity has been emphasized as a requirement toward the
burden of proof for gene–disease association studies, but has
been difficult to satisfy consistently, given the multiplicity of
variables, interactions, and inputs within these systems.
Table 1 | Glossary of common terms
Allele: Alternative form of a genetic locus; a single allele for each locus is inherited from each parent.
Candidate gene: A gene located in a chromosome region suspected of being involved in a disease. Methods to identify candidate genes include basic
science studies, identifying DNA sequences conserved across species, human genetics, or genome-wide analyses.
Epigenetics: Change in the pattern of gene expression that is mediated by mechanism other than alterations in the primary nucleotide sequence of
gene, which may or may not be heritable.
Exon: The protein-coding DNA sequence of a gene.
Genome: All the genetic material in the chromosomes of a particular organism; its size is generally given as its total number of base pairs.
Genotype: The genetic constitution of an organism, as distinguished from its physical appearance (its phenotype).
Haplotype: A way of denoting the collective genotype of a number of closely linked loci on a chromosome. A set of genetic variants that are inherited
together. Polymorphisms that are co-inherited more often than by chance alone are in linkage disequilibrium. Haplotype blocks may include many
individual polymorphisms in high-linkage disequilibrium; as a result, establishing genotype at any single polymorphic site with such a block may establish
genotypes at linked sites within the block. Individual SNPs that can be used to establish genotype within a haplotype block are termed tag-SNPs.
Intron: DNA sequence that interrupts the protein-coding sequence of a gene; an intron is transcribed into RNA but is cut out of the message before it is
translated into protein.
Linkage disequilibrium: Where alleles occur together more often than can be accounted for by chance. Indicates that the two alleles are physically close
on the DNA strand.
Phenotype: The measurable physical characteristics of an organism or the presence of a disease that may or may not be genetic. These may derive from
genotype, environment, or the combination. Organisms with the same phenotype can have different genotypes.
Polymorphisms: Difference in DNA sequence among individuals that may underlie differences in health. Genetic variations occurring in more than 1%
of a population would be considered useful polymorphisms for genetic linkage analysis. Polymorphisms can be in coding regions or more commonly, in
non-coding regions, and often vary by ethnicity. The most common type of polymorphism is a change in one nucleotide (base pair) in a DNA sequence,
referred to as an SNP. Other polymorphisms are insertion and deletion of multiple sequential nucleotides (‘indels’); variable numbers of repeats, such as
doublets or triplets; or large-scale duplications or deletions. Although some genetic variants are known to alter protein abundance or function, the
functional consequences of most polymorphisms are unknown.
SNP: DNA sequence variations that occur when a single nucleotide (A, T, C, or G) in the genome sequence is altered.
tag-SNPs: These are maximally informative SNPs that characterize common haplotypes.
SNP, single-nucleotide polymorphism.
Source: Department of Energy Human Genome Program genomics glossary (http://www.ornl.gov/sci/techresources/Human_Genome/glossary/glossary_s.shtml).
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Other caveats that must be applied to these studies include
adequate consideration of confounding and interactive
variables and intermediate phenotypes and the demonstra-
tion that alleles exist in Hardy–Weinberg equilibrium.
Without these stipulations, reports of both positive and
negative associations must be interpreted with caution.
Ongoing ancillary studies to Chronic Renal Insufficiency
Cohort (CRIC) Study40 are examining the role of inflam-
matory gene networks, upstream activators of cytokine
signaling, and cytokine signal transduction/and key inflam-
matory transcription factor pathways in the progression of
renal disease and CVD. Results from this exciting study are
expected by early 2008.
CONCEPT OF HAPLOTYPE
Considering the inconsistencies in the characterization of
associations between SNPs and intermediate and clinical
phenotypes, there is emerging interest in haplotypes (http://
www.hapmap.org). Polymorphisms do not exist in isolation,
and it may be the combination of base changes at several sites
along the gene, that is, the haplotype that influences the
function. Blocks of sequences in the same chromosome tend
to be inherited together, a phenomenon known as linkage
disequilibrium. Such groups of alleles that are rarely
separated by recombination are known as haplotypes.
Haplotypes, rather than single SNPs, may exert a concerted
effect on the phenotype of interest. Inference of common
haplotypes from genotypic information derived from tag-
SNPs may capture a large proportion of the genetic variation
across sizable regions. Thus, selection of the maximally
informative set of common tag-SNP set can comprehensively
interrogate for main effects from common functional
variation.41 The pertinent tag-SNPs may vary between
racial/ethnic groups. Several algorithms exist that help
identify the most appropriate tag-SNPs that will maximize
efficiency of study resources (http://pga.gs.washington.edu).
Commonly, the most suitable tag-SNPs are those that (a)
overlap between different race and ethnic groups, (b) overlap
with the putatively functional SNPs under study, (c)
represent unique variants for which genotyping assays are
readily available; an ordered preference for non-synonymous
SNPs, SNPs occurring in the promoter or 3-untranslated
regions, intronic and synonymous SNPs would be of greater
utility and (d) are repeat polymorphisms, which are highly
informative for haplotype construction.
A brief outline of most relevant cytokine gene poly-
morphism and their relationship to progression of renal and
CVDs is discussed below (Table 3). Gene association studies
in progressive kidney disease have not been as plentiful as
those in CVD.
IL-1 AND IL-1RA
IL-1 family consists of two proinflammatory cytokines, IL-1a
and IL-1b, and a naturally occurring anti-inflammatory
agent, the IL-1Ra. The balance between IL-1 and IL-1Ra in
local tissues plays an important role in the susceptibility to,
and severity of many diseases. Plasma IL-1 and IL-1Ra have
been shown to predict CV outcome and mortality in ESRD.
These three genes of the IL-1 complex map to the 430 kb
region on the long arm of chromosome 2. The IL-1b gene has
two base exchange (C-T) polymorphic sites at 511 and
þ 3953.50 IL-1Ra gene (IL-1RN) contains a variable number
of tandem repeat polymorphisms in intron 2. IL-1RN allele 2,
corresponding to a 2 U repeat of 86 bp, is associated with
increased production of IL-1b.27 Polymorphisms of IL-1b
and IL-1RN have also been associated with hypertension,
atherosclerosis, CAD, and progression of renal disease.42,29
INTERLEUKIN-6
IL-6 is the one of the most extensively studied effectors in the
inflammatory cascade. Elevated circulating levels have been
linked to malnutrition, hypertension, left ventricular hyper-
trophy, atherosclerosis, and CV mortality in ESRD patients51
(Figure 1). IL-6 is also an autocrine growth factor for the
mesangium. The human IL-6 gene is located at chromosome
7p21, and consists of five exons and four introns. IL-6 has
several polymorphisms in the promoter region 174 G-C,
634 C-G, 572 G-C, and 597 G-A. The promoter
region at position 373 is a polymorphic AnTn tract with six
alleles.52 The 597 G-A and 174 G-C polymorphisms
are in strong allelic association and may have an additive
effect on plasma IL-6 level.31 Different haplotypes (597
G-A/572 G-C/174 G-C) may determine the tran-
scription levels of the IL-6 gene. Associations between IL-6
gene polymorphisms (597 G-A and 174 G-C) and
CRP concentration, peripheral vascular disease, CAD, left
ventricular hypertrophy, severity of stroke cardiovascular
mortality,45 and progression of diabetic renal disease44 have
been reported.
INTERLEUKIN-10
IL-10 attenuates the inflammatory response. Decreased
production of IL-10 is associated with increased CRP and
Table 2 | Simplified summary of the putative effects of
cytokine gene polymorphisms on relative levels of cytokine
expression as determined by transcription and/or secretion
of gene product
Transcription/secretion by individual genotype
Cytokine Low Intermediate High
IL-1b27,28 511 CC 511 CT 511 TT
+3953 CC +3953 TC +3953 TT
IL-1 Ra29,30 — — Allele 2
IL-631,32 174 CC 174 GC 174 GG
572 GG 572 CG 572 CC
IL-1033,34 1082 AA 1082 GA 1082 GG
TNF-a35,36 308 GG 308 GA 308 AA
238 AA 238 GA 238 GG
— — TNFd3 allele
TGF-b37 +869 CC +869 TC +869 TT
+915 CC +915 GC +915 GG
IL, interleukin; IL-1Ra, IL-1 receptor antagonist; TGF-b, transforming growth factor-
beta; TNF-a, tumor necrosis factor-alpha.
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higher CV mortality. The IL-10 gene is located on chromo-
some 1 at 1q31–32 and is composed of five exons. IL-10 gene
has SNPs at positions 592 C-A, 819 C-T, and 1082
G-A as well as two CA repeat polymorphisms, IL-10 G and
IL-10 A approximately at positions 1200 and 4000.53 IL-
10 low producer genotype (1082 AA) is associated with
increased CV mortality in ESRD patients33 (Figure 2).
TUMOR NECROSIS FACTOR-a
TNF-a is produced early in the inflammatory reaction.
Increased TNF-a level is associated with metabolic syndrome,
CAD, left ventricular hypertrophy, and congestive cardiac
failure. TNF-a is upregulated in progressive renal disease, and
plays a role in the recruitment of inflammatory cells in
response to glomerular injury.54 The TNF-a gene is located
on chromosome 6p and is highly polymorphic.55 Known
variants in the promoter region occur at positions 1031,
863, 857, 851, 419, 376, 308, 238, 163, and
Table 3 | Cytokine gene polymorphisms known to be related to progression and severity of renal and cardiovascular diseases
Authors Genotype Clinical significance
IL-1
Amoli et al.28 511 C/T Severity of renal involvement in Henoch-Schonlein purpura
IL-1Ra
Blakemore et al.29 IL1RN*2 Development of diabetic nephropathy in type I and type II diabetes
Shu et al.42,43 IL2RN*2 Progression in IgA nephropathy and risk for ESRD
IL-6
Kitamura et al.44 634 C/G Progression of diabetic nephropathy
Liu et al.45 174 G/C Risk for CVD among dialysis patients
Losito et al.32 174 G/C LVH in hemodialysis patients, especially those with diabetes
TGF-b
Khalil et al.46 Arg25 Associated with severity of proteinuria and glomerulosclerosis
Sato et al.47 509 CC and 869 CC Heavy proteinuria and mesangial cell proliferation
Rao et al.48 G/C substitution at
codon 25
Risk for prevalent vascular disease, new onset cardiac morbidity and cardiac
mortality in HD patients
TNF-a
Thibaudin et al.49 308 G/A
TNFd2 allele Susceptibility to idiopathic membranous nephropathy
IL-10
Girndt et al.33 1082A* Lower production of IL-10 and increased CV morbidity
CVD, cardiovascular disease; ESRD, end-stage renal disease; HD, hemodialysis; IL, interleukin; LVH, left ventricular hypertrophy.
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Figure 1 | Results from a study of hemodialysis patients
exemplifying the association between cytokine levels and
survival. The figure shows the adjusted event-free survival by
quartiles of baseline plasma IL-6 levels for all-cause mortality in ESRD
patients. Patients in the highest quartile of baseline plasma Il-6 level
had an adjusted hazard for all-cause mortality of 1.85 times that of
lowest reference quartile (from Rao et al.51).
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Figure 2 | Results from a study of hemodialysis patients
exemplifying the association between cytokine gene
polymorphisms and survival. The figure shows the cardiovascular
event-free survival in ESRD patients with IL-10 gene polymorphism at
position 1082. Patients homozygous for 1082A had a significantly
shorter event-free survival compared to those with 1082G
genotype (P¼ 0.004, all three patient groups) (from Girndt et al.33).
Kidney International (2007) 72, 549–556 553
M Rao et al.: Cytokine gene polymorphism m i n i r e v i e w
49 relative to the transcription start site and also þ 488 in
the intron. Most of these SNPs are G-A substitution, with
the exception of 419 (G-C), 851 (C-T), 857 (C-A),
863 (C-A), and 1031 (T-C). TNFd microsatellite
polymorphism (TNFd1–d7) consists of various dinucleotide
repeats (GA) located 8 kb downstream the TNF-a gene.56
Polymorphisms of TNF-a gene at 308 and 238 positions
are related to metabolic syndrome, CAD, and stroke.57
Recently, investigators reported that SNP at position 308 in
the promoter region and TNFd2 allele are associated with
susceptibility to idiopathic membranous nephropathy, but
did not predict disease progression.58
TRANSFORMING GROWTH FACTOR-b
TGF-b has anti-atherogenic and anti-inflammatory proper-
ties. Overproduction of TGF-b has been linked to hyperten-
sion, left ventricular hypertrophy, vascular remodeling, and
progressive renal disease. Increased circulating level of TGF-b
may accelerate the deterioration of renal function by
accumulation of matrix proteins, interstitial fibrosis, and
mesangial expansion. Seven polymorphisms have been
identified in the TGF-b gene, including two in the signal
peptide sequence Leu10-Pro (þ 869 T-C) and Arg25-Pro
(þ 915 G-C).59 The proline allele at codon 10 (Pro10) is
associated with higher levels of TGF-b mRNA and protein.
The codon 25 G/G genotype is associated with higher plasma
levels of TGF-b than the G/C genotype. TGF-b codon 10 and
codon 25 genotypes have been shown to be related to CAD,
hypertension, and myocardial infarction.59 Rao et al.48
demonstrated that the G/C substitution at codon 25 is
associated with an increased risk for prevalent vascular
disease and new onset cardiac morbidity, and mortality in
ESRD patients.
CACHEXIA, INFLAMMATION AND CVD
Malnutrition and cachexia coexist with inflammation in
CKD. A number of investigators have demonstrated that
inflammation may play a key role in the pathogenesis of
protein energy wasting in CKD. Plasma levels of pro-
inflammatory cytokines have been shown to be inversely
related to serum albumin and muscle mass. Prevalence and
severity of the malnutrition inflammation atherosclerosis
syndrome is strongly associated with CVD and all-cause
mortality in patients with ESRD.60 SNPs in the promoter
region of the proinflammatory cytokines IL-6 and TNF-a,
and the regulatory monokine IL-10, show a strong associa-
tion with indices of comorbidity and nutritional markers in
ESRD patients.35 Interestingly, some of the genes regulating
skeletal muscle mass are also associated with insulin
resistance, inflammation pathway, and cardiac morphology.61
OTHER STRUCTURAL VARIATIONS IN THE GENOME
Emerging role of epigenetics
Epigenetic alterations are potentially reversible changes in
genetic material leading to alterations in gene expression. The
best-known epigenetic signal is DNA methylation, which is
frequently associated with transcriptional silencing of genes.
Global hypomethylation may promote genomic instability.
DNA hypermethylation may contribute to upregulation of
atherosclerosis-susceptible genes and downregulation of
atherosclerosis-protective genes and affect genes that mediate
progression of renal disease. Epigenetic alterations in
monocarboxylate transporter and estrogen receptor a genes
that alter inflammatory response and induce phenotypic
transition of smooth muscle cells have been described.
Change in methylation status can modulate B- and T-cell
differentiation and also production of cytokines.62
Copy-number variants
These are gains and losses of DNA sequences of 41 kb that
may include genes resulting in differential levels of gene
expression and accounting for a significant proportion of
normal phenotypic variation. A recently described example
of a segmental duplication encompasses the gene encoding
CCL3L1, a potent HIV-1 suppressive chemokine and ligand
for the HIV co-receptor CCR5, that influences the suscepti-
bility to AIDS.63
WHY IS STUDYING CYTOKINE GENE POLYMORPHISM IM-
PORTANT?
The rationale for studying cytokine gene polymorphism and
their inferred haplotypes are to (a) understand the cause for
interindividual variation in inflammatory response, dete-
rioration of renal function, and progression of CVD,
(b) identify CKD patients at high risk for susceptibility,
severity, and poor clinical outcomes, (c) develop novel
strategies to prevent or delay the disease process, and (d)
enhance the understanding of the etiopathogenesis of
increased CVD in patients with CKD. One often overlooked
aspect of cytokine gene–disease association studies is that the
cytokine network is highly complex, containing interactive
cascades of gene activation and suppression. Therefore,
individual polymorphisms in cytokine genes association
may be non-informative, whereas specific combinations of
cytokine genotypes or the activation of specific cytokines in a
given context might predispose to disease susceptibility or
outcome. An example is the West of Scotland Coronary
Prevention Study (WOSCOPS),64 where there was no
significant evidence of higher risk associated with the
174CC IL-6 genotype compared with the GGþGC group
in the placebo arm. However, in the pravastatin-treated
group, CC homozygotes had a significantly lower risk of CVD
compared with the GGþGC placebo group, suggesting that
the early intervention was most effective among patients with
high-risk genotypes. Thus, it is reasonable to speculate that
early interventions in CKD patients with high-risk genotypes
might slow the progression of renal disease and also decrease
CV mortality and morbidity.
To summarize, the rates of progression of CKD and CVD
show wide interindividual variation, even when corrected for
potential confounding influences. Cytokines, interacting with
environmental and traditional risk factors, could modulate
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the risk for progression of renal disease and the susceptibility
to and/or progression of CVD. Polymorphisms of cytokine
genes may influence the expression of gene and their gene
products. Those SNPs and their inferred haplotypes that
promote increased transcription of proinflammatory cyto-
kines may be associated with risk for and also progression of
renal and CVDs. Identification of patients carrying high-risk
genotypes may allow early and aggressive interventions to be
aimed at appropriate target populations.
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